ArticleFrontiers in immunology2017
Analysis of the Phenotype of
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 79 citations in OpenAlex.
- Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection.The Journal of clinical investigation · 2021Trial
- IFNγ blockade in Mycobacterium tuberculosis infected macaques alters the granuloma environment but not bacterial control.Nature communications · 2026Article
- Optimisation and application of a T-cell antigen-specific activation assay as diagnostic and treatment-monitoring tool for tuberculosis.ERJ open research · 2026Article
- Host response biomarkers of tuberculosis recurrence and treatment failure.Communications medicine · 2026Article
- Comparative Performance of Flow Cytometry and ELISA for Detecting Ki-67 and HLA-DR in Whole Blood: Implications for Tuberculosis Diagnosis and Treatment Monitoring.Journal of pharmacy & bioallied sciences · 2025Article
- HIV co-infection is associated with increased HLA-DR expression by Mycobacterium tuberculosis-specific CD4 T cells in people with latent tuberculosis infection.Tuberculosis (Edinburgh, Scotland) · 2025Article
- Activation and proliferation profiles of M.tuberculosis specific dual functional CD4+T cells from smear negative pulmonary TB patients.PloS one · 2025Article
- Differentiating Latent Tuberculosis from Active Tuberculosis Through Activation Phenotypes and Chemokine Markers HLA-DR, CD38, MCP-1, and RANTES: A Systematic Review and Meta-Analysis.Biomarker insights · 2025Article
- T Cell Responses during Human Immunodeficiency Virus/Vaccines · 2024Review
- Polarization of HIV-1- and CMV-Specific IL-17-Producing T Cells among People with HIV under Antiretroviral Therapy with Cannabis and/or Cocaine Usage.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Changes of Mycobacterium tuberculosis specific antigen-stimulated CD27European journal of medical research · 2024Article
- Specific immune response toFrontiers in immunology · 2024Article
- Blood and Site of Disease Inflammatory Profiles Differ in Patients With Pericardial Tuberculosis and Human Immunodeficiency Virus Type 1.Open forum infectious diseases · 2023Article
- Diagnosis and biomarkers for ocular tuberculosis: From the present into the future.Theranostics · 2023Review
- Metabolites enhance innate resistance to human Mycobacterium tuberculosis infection.JCI insight · 2022Article
- Tuberculosis Treatment Response Monitoring by the Phenotypic Characterization ofPathogens (Basel, Switzerland) · 2022Article
- Characterization ofJournal of immunology (Baltimore, Md. : 1950) · 2022Article
- Article
- Assessment of tuberculosis disease activity in people infected withEClinicalMedicine · 2022Article
- Defining the Role of Cellular Immune Signatures in Diagnostic Evaluation of Suspected Tuberculosis.The Journal of infectious diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
Several immune-based assays have been suggested to differentiate latent from active tuberculosis (TB). However, their relative performance as well as their efficacy in HIV-infected persons, a highly at-risk population, remains unclear. In a study of 81 individuals, divided into four groups based on their HIV-1 status and TB disease activity, we compared the differentiation (CD27 and KLRG1), activation (HLA-DR), homing potential (CCR4, CCR6, CXCR3, and CD161) and functional profiles (IFNγ, IL-2, and TNFα) of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.